Skip to content
OpenCapital
Get started

Aurinia Pharmaceuticals AUPH Japan — Revenue

Other geography segments

U.S.
$157.96M+54.2%

Similar metrics at other companies

Exelixis logo
EXELJapan — Total revenues
$12.7M+129%
SoundHound AI, Inc. logo
SOUNJapan — Revenue
$4.58M+1,508%
Krystal Biotech, Inc. logo
KRYSJapan — Product revenue, net
$8.19M—
Haemonetics logo
HAEJapan — Net revenues
$18.4M+14.3%
NovoCure logo
NVCRJapan — Net revenues
$10.24M+17.6%
Nuvation Bio logo
NUVBJP — Revenue
$652K+256%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Aurinia Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's japan — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's japan — revenue?
Aurinia Pharmaceuticals (AUPH) reported japan — revenue of $4.8M in Q4 2025.
How has Aurinia Pharmaceuticals's japan — revenue changed year-over-year?
Aurinia Pharmaceuticals's japan — revenue decreased by 23.3% year-over-year, from $6.26M to $4.8M.
What does japan — revenue mean?
This metric represents the total gross revenue generated from pharmaceutical product sales and licensing activities within the Japanese geographic market. It serves as a key indicator of the company's international commercial footprint and the successful adoption of its therapeutic portfolio in this specific region. Monitoring this figure helps investors assess the company's ability to navigate foreign regulatory environments and capture market share outside of its primary domestic territory.